Table of Content

1 Report Overview

1.1 Study Scope and Definition

1.2 Research Methodology

1.2.1 Methodology/Research Approach

1.2.2 Data Source

1.3 Key Market Segments

1.4 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Therapeutic Revenue

1.5 Market Analysis by Type

1.5.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Type: 2021 VS 2027

1.5.2 Nusinersen

1.5.3 Onasemnogen Abeparvovec

1.6 Market by Application

1.6.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2022-2027

1.6.2 Nusinersen SMA

1.6.3 Onasemnogen Abeparvovec SMA

1.6.4 Other

1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2021 and 2022 Projections

1.7.2 Covid-19 Impact: Commodity Prices Indices

1.7.3 Covid-19 Impact: Global Major Government Policy

1.8 Study Objectives

1.9 Years Considered

2 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Trends and Growth Strategy

2.1 Market Top Trends

2.2 Market Drivers

2.3 Market Challenges

2.4 Porter’s Five Forces Analysis

2.5 Market Growth Strategy

2.6 SWOT Analysis

3 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Players Profiles

3.1 Biogen

3.1.1 Biogen Company Profile

3.1.2 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

3.1.3 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

3.2 Astellas Pharma

3.2.1 Astellas Pharma Company Profile

3.2.2 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

3.2.3 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

3.3 Novartis

3.3.1 Novartis Company Profile

3.3.2 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

3.3.3 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

3.4 Roche

3.4.1 Roche Company Profile

3.4.2 Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

3.4.3 Roche Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

3.5 Genzyme Corporation

3.5.1 Genzyme Corporation Company Profile

3.5.2 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

3.5.3 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

4 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Competition by Market Players

4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity Market Share by Market Players (2016-2021)

4.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Market Players (2016-2021)

4.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Average Price by Market Players (2016-2021)

5 Global Spinal Muscular Atrophy (SMA) Therapeutic Production by Regions (2016-2021)

5.1 North America

5.1.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.1.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in North America (2016-2021)

5.1.3 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.1.4 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.2 East Asia

5.2.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.2.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in East Asia (2016-2021)

5.2.3 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.2.4 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.3 Europe

5.3.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.3.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Europe (2016-2021)

5.3.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.3.4 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.4 South Asia

5.4.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.4.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in South Asia (2016-2021)

5.4.3 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.4.4 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.5 Southeast Asia

5.5.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.5.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Southeast Asia (2016-2021)

5.5.3 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.5.4 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.6 Middle East

5.6.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.6.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Middle East (2016-2021)

5.6.3 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.6.4 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.7 Africa

5.7.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.7.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Africa (2016-2021)

5.7.3 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.7.4 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.8 Oceania

5.8.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.8.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Oceania (2016-2021)

5.8.3 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.8.4 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.9 South America

5.9.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.9.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in South America (2016-2021)

5.9.3 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.9.4 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

5.10 Rest of the World

5.10.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2016-2021)

5.10.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Rest of the World (2016-2021)

5.10.3 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021)

5.10.4 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021)

6 Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Region (2016-2021)

6.1 North America

6.1.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.1.2 United States

6.1.3 Canada

6.1.4 Mexico

6.2 East Asia

6.2.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.2.2 China

6.2.3 Japan

6.2.4 South Korea

6.3 Europe

6.3.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.3.2 Germany

6.3.3 United Kingdom

6.3.4 France

6.3.5 Italy

6.3.6 Russia

6.3.7 Spain

6.3.8 Netherlands

6.3.9 Switzerland

6.3.10 Poland

6.4 South Asia

6.4.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.4.2 India

6.5 Southeast Asia

6.5.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.5.2 Indonesia

6.5.3 Thailand

6.5.4 Singapore

6.5.5 Malaysia

6.5.6 Philippines

6.6 Middle East

6.6.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.6.2 Turkey

6.6.3 Saudi Arabia

6.6.4 Iran

6.6.5 United Arab Emirates

6.7 Africa

6.7.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.7.2 Nigeria

6.7.3 South Africa

6.8 Oceania

6.8.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.8.2 Australia

6.9 South America

6.9.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

6.9.2 Brazil

6.9.3 Argentina

6.10 Rest of the World

6.10.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

7 Global Spinal Muscular Atrophy (SMA) Therapeutic Production Forecast by Regions (2022-2027)

7.1 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic (2022-2027)

7.2 Global Forecasted Revenue of Spinal Muscular Atrophy (SMA) Therapeutic (2022-2027)

7.3 Global Forecasted Price of Spinal Muscular Atrophy (SMA) Therapeutic (2022-2027)

7.4 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic by Region (2022-2027)

7.4.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.2 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.4 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.5 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.6 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.7 Africa Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.8 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.9 South America Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.4.10 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2022-2027)

7.5 Forecast by Type and by Application (2022-2027)

7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)

7.5.2 Global Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Application (2022-2027)

8 Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast by Regions (2022-2027)

8.1 North America Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.2 East Asia Market Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.3 Europe Market Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Countriy

8.4 South Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.5 Southeast Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.6 Middle East Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.7 Africa Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.8 Oceania Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.9 South America Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

8.10 Rest of the world Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

9 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales by Type (2016-2027)

9.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Type (2016-2021)

9.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Type (2022-2027)

10 Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Application (2016-2027)

10.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Application (2016-2021)

10.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Application (2022-2027)

11 Global Spinal Muscular Atrophy (SMA) Therapeutic Manufacturing Cost Analysis

11.1 Spinal Muscular Atrophy (SMA) Therapeutic Key Raw Materials Analysis

11.1.1 Key Raw Materials

11.2 Proportion of Manufacturing Cost Structure

11.3 Manufacturing Process Analysis of Spinal Muscular Atrophy (SMA) Therapeutic

12 Global Spinal Muscular Atrophy (SMA) Therapeutic Marketing Channel, Distributors, Customers and Supply Chain

12.1 Marketing Channel

12.2 Spinal Muscular Atrophy (SMA) Therapeutic Distributors List

12.3 Spinal Muscular Atrophy (SMA) Therapeutic Customers

12.4 Spinal Muscular Atrophy (SMA) Therapeutic Supply Chain Analysis

13 Analyst's Viewpoints/Conclusions

14 Disclaimer

List of Figure

Table 1. Research Programs/Design for This Report

Table 2. Key Data Information from Secondary Sources

Table 3. Key Executives Interviewed

Table 4. Key Data Information from Primary Sources

Table 5. Key Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$ Million) 2016-2021

Table 6. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (US$ Million): 2022-2027

Table 7. Nusinersen Features

Table 8. Onasemnogen Abeparvovec Features

Table 16. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (US$ Million): 2022-2027

Table 17. Nusinersen SMA Case Studies

Table 18. Onasemnogen Abeparvovec SMA Case Studies

Table 19. Other Case Studies

Table 26. Overview of the World Economic Outlook Projections

Table 27. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 28. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 29. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 30. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 31. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 32. Commodity Prices-Metals Price Indices

Table 33. Commodity Prices- Precious Metal Price Indices

Table 34. Commodity Prices- Agricultural Raw Material Price Indices

Table 35. Commodity Prices- Food and Beverage Price Indices

Table 36. Commodity Prices- Fertilizer Price Indices

Table 37. Commodity Prices- Energy Price Indices

Table 38. G20+: Economic Policy Responses to COVID-19

Table 39. Covid-19 Impact: Global Major Government Policy

Table 40. Spinal Muscular Atrophy (SMA) Therapeutic Report Years Considered

Table 41. Market Top Trends

Table 42. Key Drivers: Impact Analysis

Table 43. Key Challenges

Table 44. Porter's Five Forces Analysis

Table 45. Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Strategy

Table 46. Spinal Muscular Atrophy (SMA) Therapeutic SWOT Analysis

Table 47. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 48. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table 49. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 50. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table 51. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 52. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table 53. Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 54. Table Roche Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table 55. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 56. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table 147. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity by Market Players

Table 148. Global Spinal Muscular Atrophy (SMA) Therapeutic Production by Market Players (2016-2021)

Table 149. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Market Share by Market Players (2016-2021)

Table 150. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Market Players (2016-2021)

Table 151. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Market Players (2016-2021)

Table 152. Global Market Spinal Muscular Atrophy (SMA) Therapeutic Average Price of Key Market Players (2016-2021)

Table 153. North America Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 154. North America Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 155. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 156. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 157. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 158. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 159. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 160. East Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 161. East Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 162. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 163. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 164. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 165. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 166. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 167. Europe Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 168. Europe Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 169. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 170. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 171. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 172. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 173. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 174. South Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 175. South Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 176. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 177. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 178. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 179. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 180. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 181. Southeast Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 182. Southeast Asia Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 183. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 184. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 185. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 186. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 187. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 188. Middle East Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 189. Middle East Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 190. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 191. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 192. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 193. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 194. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 195. Africa Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 196. Africa Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 197. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 198. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 199. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 200. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 201. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 202. Oceania Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 203. Oceania Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 204. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 205. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 206. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 207. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 208. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 209. South America Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 210. South America Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 211. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 212. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 213. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 214. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 215. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Table 216. Rest of the World Key Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue (2016-2021) (US$ Million)

Table 217. Rest of the World Key Players Spinal Muscular Atrophy (SMA) Therapeutic Market Share (2016-2021)

Table 218. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 219. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type (2016-2021)

Table 220. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 221. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application (2016-2021)

Table 222. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 223. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 224. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Region (2016-2021)

Table 225. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 226. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 227. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 228. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 229. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 230. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 231. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2016-2021)

Table 232. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Forecast by Region (2022-2027)

Table 233. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Forecast by Type (2022-2027)

Table 234. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Market Share Forecast by Type (2022-2027)

Table 235. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Forecast by Type (2022-2027)

Table 236. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Market Share Forecast by Type (2022-2027)

Table 237. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Price Forecast by Type (2022-2027)

Table 238. Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Volume Forecast by Application (2022-2027)

Table 239. Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Value Forecast by Application (2022-2027)

Table 240. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 241. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 242. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 243. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 244. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 245. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 246. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 247. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 248. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 249. Rest of the world Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027 by Country

Table 250. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2016-2021) (US$ Million)

Table 251. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type (2016-2021)

Table 252. Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Type (2022-2027) (US$ Million)

Table 253. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type (2022-2027)

Table 254. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2016-2021) (US$ Million)

Table 255. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application (2016-2021)

Table 256. Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Application (2022-2027) (US$ Million)

Table 257. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application (2022-2027)

Table 258. Spinal Muscular Atrophy (SMA) Therapeutic Distributors List

Table 259. Spinal Muscular Atrophy (SMA) Therapeutic Customers List





Figure 1. Product Figure

Figure 2. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type: 2021 VS 2027

Figure 3. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2021 VS 2027

Figure 4. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2016-2021) (US$ Million)

Figure 5. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 6. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 7. United States Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 8. Canada Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 9. Mexico Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 10. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 11. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 12. China Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 13. Japan Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 14. South Korea Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 15. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 16. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Region in 2021

Figure 17. Germany Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 18. United Kingdom Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 19. France Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 20. Italy Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 21. Russia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 22. Spain Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 23. Netherlands Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 24. Switzerland Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 25. Poland Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 26. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 27. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 28. India Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 29. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 30. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 31. Indonesia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 32. Thailand Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 33. Singapore Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 34. Malaysia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 35. Philippines Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 36. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 37. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 38. Turkey Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 39. Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 40. Iran Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 41. United Arab Emirates Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 42. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 43. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 44. Nigeria Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 45. South Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 46. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 47. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 48. Australia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 49. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 50. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 51. Brazil Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 52. Argentina Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2016-2021)

Figure 53. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 54. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2021

Figure 55. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity Growth Rate Forecast (2022-2027)

Figure 56. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 57. Global Spinal Muscular Atrophy (SMA) Therapeutic Price and Trend Forecast (2022-2027)

Figure 58. North America Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 59. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 60. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 61. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 62. Europe Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 63. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 64. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 65. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 66. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 67. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 68. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 69. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 70. Africa Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 71. Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 72. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 73. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 74. South America Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 75. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 76. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2022-2027)

Figure 77. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2022-2027)

Figure 78. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 79. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 80. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 81. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 82. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 83. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 84. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 85. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 86. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 87. Rest of the world Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2022-2027

Figure 88. Manufacturing Cost Structure of Spinal Muscular Atrophy (SMA) Therapeutic

Figure 89. Manufacturing Process Analysis of Spinal Muscular Atrophy (SMA) Therapeutic

Figure 90. Channels of Distribution

Figure 91. Distributors Profiles

Figure 92. Spinal Muscular Atrophy (SMA) Therapeutic Supply Chain Analysis